370 related articles for article (PubMed ID: 31776785)
21. Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues.
Agarwal P; Mohamed A
Curr Treat Options Oncol; 2022 Sep; 23(9):1233-1246. PubMed ID: 35939200
[TBL] [Abstract][Full Text] [Related]
22. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
Krug S; Mordhorst JP; Moser F; Theuerkorn K; Ruffert C; Egidi M; Rinke A; Gress TM; Michl P
PLoS One; 2019; 14(6):e0218953. PubMed ID: 31237925
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.
Fazio N; Cella CA; Del Re M; Laffi A; Rubino M; Zagami P; Spada F
Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):993-1004. PubMed ID: 31794273
[No Abstract] [Full Text] [Related]
24. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
25. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
26. The safety of available treatments options for neuroendocrine tumors.
Faggiano A; Lo Calzo F; Pizza G; Modica R; Colao A
Expert Opin Drug Saf; 2017 Oct; 16(10):1149-1161. PubMed ID: 28705090
[TBL] [Abstract][Full Text] [Related]
27. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT; Kunz PL; Reidy-Lagunes DL
Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
[TBL] [Abstract][Full Text] [Related]
28. Systemic therapy for advanced pancreatic neuroendocrine tumors.
Kulke MH
Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
[TBL] [Abstract][Full Text] [Related]
29. The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors.
Cives M; Pelle' E; Quaresmini D; Mandriani B; Tucci M; Silvestris F
Curr Treat Options Oncol; 2019 Jul; 20(9):72. PubMed ID: 31346813
[TBL] [Abstract][Full Text] [Related]
30. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
31. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L
Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic neuroendocrine tumors: a review.
Young K; Iyer R; Morganstein D; Chau I; Cunningham D; Starling N
Future Oncol; 2015; 11(5):853-64. PubMed ID: 25757686
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic neuroendocrine neoplasms.
Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
[TBL] [Abstract][Full Text] [Related]
34. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?
Rodriguez-Freixinos V; Thawer A; Capdevila J; Ferone D; Singh S
Curr Oncol Rep; 2021 May; 23(7):80. PubMed ID: 33937962
[TBL] [Abstract][Full Text] [Related]
35. Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms.
Vijayvergia N; Dasari A
Curr Treat Options Oncol; 2020 Oct; 21(12):96. PubMed ID: 33029680
[TBL] [Abstract][Full Text] [Related]
36. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Chan JA; Kulke MH
Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
[TBL] [Abstract][Full Text] [Related]
37. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
Pea A; Hruban RH; Wood LD
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Uprety D; Halfdanarson TR; Molina JR; Leventakos K
Curr Treat Options Oncol; 2020 Aug; 21(11):86. PubMed ID: 32862320
[TBL] [Abstract][Full Text] [Related]
39. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
40. [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Ito T; Igarashi H; Jensen RT; Takayanagi R
Fukuoka Igaku Zasshi; 2012 Jul; 103(7):131-7. PubMed ID: 22978065
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
